NCT03910530View on ClinicalTrials.gov

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions
Advanced Solid TumorsMetastatic Solid Tumors
Interventions
DRUG

Retifanlimab

Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.

DRUG

INCB001158

Part 1: INCB001158 75 or 100 mg twice daily administered orally.

DRUG

Retifanlimab + INCB001158

Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .

Trial Locations (2)

1040045

National Cancer Center Hospital, Chūōku

277-8577

National Cancer Center Hospital East, Kashiwa

Sponsors
All Listed Sponsors
lead

Incyte Biosciences Japan GK

INDUSTRY

NCT03910530 - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter